The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model
Open accessAbstract
Purpose: Advanced-stage mycosis fungoides (MF; stage IIB to IV) and Sézary syndrome (SS) are aggressive lymphomas with a median survival of 1 to 5 years. Clinical management is stage based; however, there is wide range of outcome within stages. Published prognostic studies in MF/SS have been single-center trials. Because of the rarity of MF/SS, only a large collaboration would power a study to identify independent prognostic markers. Patients and Methods: Literature review identified the following 10 candidate markers: stage, age, sex, cutaneous histologic features of folliculotropism, CD30 positivity, proliferation index, large-cell transformation, WBC/lymphocyte count, serum lactate dehydrogenase, and identical T-cell clone in blood and skin. Data were collected at specialist centers on patients diagnosed with advanced-stage MF/SS from 2007. Each parameter recorded at diagnosis was tested against overall survival (OS). Results: Staging data on 1,275 patients with advanced MF/SS from 29 international sites were included for survival analysis. The median OS was 63 months, with 2- and 5-year survival rates of 77% and 52%, respectively. The median OS for patients with stage IIB disease was 68 months, but patients diagnosed with stage III disease had slightly improved survival compared with patients with stage IIB, although patients diagnosed with stage IV disease had significantly worse survival (48 months for stage IVA and 33 months for stage IVB). Of the 10 variables tested, four (stage IV, age > 60 years, large-cell transformation, and increased lactate dehydrogenase) were independent prognostic markers for a worse survival. Combining these four factors in a prognostic index model identified the following three risk groups across stages with significantly different 5-year survival rates: low risk (68%), intermediate risk (44%), and high risk (28%). Conclusion: To our knowledge, this study includes the largest cohort of patients with advanced-stage MF/SS and identifies markers with independent prognostic value, which, used together in a prognostic index, may be useful to stratify advanced-stage patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO-EORTC classification for cutaneous lymphomas
Willemze, R. (2005) · Blood · doi:10.1182/blood-2004-09-3502 · Cited by 3,803
Self-citationOlsen, E., Vonderheid, E., Pimpinelli, N., Willemze, R., Kim, Y., Knobler, R., Zackheim, H., Duvic, M., Estrach, T., Lamberg, S., et al. (2007) · Blood · doi:10.1182/blood-2007-03-055749 · Cited by 1,429
Self-citationFollicular lymphoma international prognostic index
Solal-Celigny, P. (2006) · Current Treatment Options in Oncology · doi:10.1007/s11864-006-0036-3 · Cited by 1,339
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin-Nelemans, H. C., Pfreundschuh, M., Reiser, M., Metzner, B., Einsele, H., et al. (2008) · Blood · doi:10.1182/blood-2007-06-095331 · Cited by 984
Thiers, B. H. (2008) · Yearbook of Dermatology and Dermatologic Surgery · doi:10.1016/s0093-3619(08)70989-4 · Cited by 974
Agar, N. S., Wedgeworth, E., Crichton, S., Mitchell, T. J., Cox, M., Ferreira, S., Robson, A., Calonje, E., Stefanato, C. M., Wain, E. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7665 · Cited by 853
Self-citationKim, Y. H., Liu, H. L., Mraz-Gernhard, S., Varghese, A., & Hoppe, R. T. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.7.857 · Cited by 653
Self-citationFollicular Lymphoma International Prognostic Index
Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2003-12-4434 · Cited by 626
Mycosis Fungoides: Disease Evolution and Prognosis of 309 Dutch Patients
van Doorn, R., Van Haselen, C. W., van Voorst Vader, P. C., Geerts, M.-L., Heule, F., de Rie, M., Steijlen, P. M., Dekker, S. K., van Vloten, W. A., & Willemze, R. (2000) · Archives of Dermatology · doi:10.1001/archderm.136.4.504 · Cited by 367
Self-citationvan Doorn, R., Scheffer, E., & Willemze, R. (2002) · Archives of Dermatology · doi:10.1001/archderm.138.2.191 · Cited by 331
Self-citationLong-term Outcomes of 1,263 Patients with Mycosis Fungoides and Sézary Syndrome from 1982 to 2009
Talpur, R., Singh, L., Daulat, S., Liu, P., Seyfer, S., Trynosky, T., Wei, W., & Duvic, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0604 · Cited by 289
Self-citationPrognostic factors in aggressive non-Hodgkin's lymphoma: who has "high- risk" disease?
Shipp, M. (1994) · Blood · doi:10.1182/blood.v83.5.1165.1165 · Cited by 278
Vergier, B., Muret, A. D., Beylot-Barry, M., Vaillant, L., Ekouévi, D. K., Chêne, G., Carlotti, A., Franck, N., Dechelotte, P., Souteyrand, P., et al. (2000) · PubMed · doi:10.1182/blood.v95.7.2212 · Cited by 263
Self-citationFolliculotropic Mycosis Fungoides: An Aggressive Variant of Cutaneous T-Cell Lymphoma
Gerami, P., Rosen, S., Kuzel, T., Boone, S. L., & Guitart, J. (2008) · Archives of Dermatology · doi:10.1001/archderm.144.6.738 · Cited by 232
Self-citationPrognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases
Benner, M. F., Jansen, P. M., Vermeer, M. H., & Willemze, R. (2012) · Blood · doi:10.1182/blood-2011-08-376319 · Cited by 215
Self-citationPrognostic factor analysis in mycosis fungoides/Sézary syndrome
Diamandidou, E., Colome, M., Fayad, L., Duvic, M., & Kurzrock, R. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70079-4 · Cited by 172
Self-citationBenton, E. C., Crichton, S., Talpur, R., Agar, N. S., Fields, P. A., Wedgeworth, E., Mitchell, T. J., Cox, M., Ferreira, S., Liu, P., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.018 · Cited by 158
Self-citationScarisbrick, J. J., Kim, Y. H., Whittaker, S. J., Wood, G. S., Vermeer, M. H., Prince, H. M., & Quaglino, P. (2014) · British Journal of Dermatology · doi:10.1111/bjd.12909 · Cited by 154
Self-citationFolliculotropic Mycosis Fungoides
Lehman, J. S., Cook‐Norris, R. H., Weed, B. R., Weenig, R. H., Gibson, L. E., Weaver, A. L., & Pittelkow, M. R. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2010.101 · Cited by 148
Quaglino, P., Pimpinelli, N., Berti, E., Calzavara‐Pinton, P., Lombardo, G. A., Rupoli, S., Alaibac, M., Bottoni, U., Carbone, A., Fava, P., et al. (2012) · Cancer · doi:10.1002/cncr.27627 · Cited by 138
Self-citationFolliculotropic mycosis fungoides: Clinicopathological features and outcome in a series of 20 cases
Muniesa, C., Estrach, T., Pujol, R. M., Gallardo, F., García‐Muret, P., Climent, F., & Servitje, O. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.03.014 · Cited by 119
Self-citationCD30 Expression and Proliferative Fraction in Nontransformed Mycosis Fungoides
Edinger, J. T., Clark, B. Z., Pucevich, B., Geskin, L. J., & Swerdlow, S. H. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181bf677d · Cited by 117
Vidulich, K. A., Talpur, R., Bassett, R. L., & Duvic, M. A. (2009) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2009.03771.x · Cited by 115
Self-citationPrognostic Value of Blood Eosinophilia in Primary Cutaneous T-Cell Lymphomas
Tancrède‐Bohin, E., Ionescu, M., Salmonière, P. D. L., Dupuy, A., Rivet, J., Rybojad, M., Dubertret, L., Bachelez, H., Lebbé, C., & Morel, P. (2004) · Archives of Dermatology · doi:10.1001/archderm.140.9.1057 · Cited by 105
Klemke, C. D., Booken, N., Weiss, C., Nicolay, J. P., Goerdt, S., Felcht, M., Géraud, C., Kempf, W., Assaf, C., Ortonne, N., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13832 · Cited by 94
Self-citationPrognosis of 100 Japanese patients with mycosis fungoides and Sézary syndrome
Suzuki, S., Ito, K., Ito, M., & Kawai, K. (2009) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2009.10.010 · Cited by 53
Cited by
Kim, Y. H., Bagot, M., Pinter-Brown, L., Rook, A. H., Porcu, P., Horwitz, S. M., Whittaker, S., Tokura, Y., Vermeer, M., Zinzani, P. L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30379-6 · Cited by 669
Self-citationTrautinger, F., Eder, J., Assaf, C., Bagot, M., Cozzio, A., Dummer, R., Gniadecki, R., Klemke, C.-D., Ortiz-Romero, P. L., Papadavid, E., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.027 · Cited by 452
Self-citationWillemze, R., Hodak, E., Zinzani, P. L., Specht, L., & Ladetto, M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy133 · Cited by 281
Self-citationScarisbrick, J. J., Quaglino, P., Prince, H. M., Papadavid, E., Hodak, E., Bagot, M., Servitje, O., Berti, E., Ortiz‐Romero, P., Stadler, R., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17258 · Cited by 244
Self-citationDoeleman, T., Hondelink, L. M., Vermeer, M. H., van Dijk, M. R., & Schrader, A. M. R. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.06.004 · Cited by 26
Self-citation
Metadata
- Authors
- Scarisbrick, J. J., Prince, H. M., Vermeer, M. H., Quaglino, P., Horwitz, S., Porcu, P., Stadler, R., Wood, G. S., Beylot-Barry, M., Pham-Ledard, A., Foss, F., Girardi, M., Bagot, M., Michel, L., Battistella, M., Guitart, J., Kuzel, T. M., Martinez-Escala, M. E., Estrach, T., Papadavid, E., Antoniou, C., Rigopoulos, D., Nikolaou, V., Sugaya, M., Miyagaki, T., Gniadecki, R., Sanches, J. A., Cury-Martins, J., Miyashiro, D., Servitje, O., Muniesa, C., Berti, E., Onida, F., Corti, L., Hodak, E., Amitay-Laish, I., Ortiz-Romero, P. L., Rodríguez-Peralto, J. L., Knobler, R., Porkert, S., Bauer, W., Pimpinelli, N., Grandi, V., Cowan, R., Rook, A., Kim, E., Pileri, A., Patrizi, A., Pujol, R. M., Wong, H., Tyler, K., Stranzenbach, R., Querfeld, C., Fava, P., Maule, M., Willemze, R., Evison, F., Morris, S., Twigger, R., Talpur, R., Kim, J., Ognibene, G., Li, S., Tavallaee, M., Hoppe, R. T., Duvic, M., Whittaker, S. J., & Kim, Y. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-11-10
- Volume
- 33
- Issue
- 32
- Pages
- 3766-3773
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1877715550
- Cited by
- 430
- References
- 26
- FWCI
- 32.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.